Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma.
Nicholas J HornsteinMohammad A ZeineddineBetul Beyza GunesAndrew J PellattMark KnaflHaifeng ZhuAnneleis F WillettAbdelrahman M G YousefSuyu LiuRyan SunP Andrew FutrealScott E WoodmanMelissa W TaggartMichael James OvermanDaniel M HalperinKanwal P S RaghavJohn Paul ShenPublished in: Cancer research communications (2024)
In light of recent data demonstrating a lack of efficacy of 5-FU based chemotherapy, Atezo+Bev is a promising treatment option for patients with low-grade unresectable AA; further study is warranted.